These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
11. A review of sitaxsentan sodium in patients with pulmonary arterial hypertension. Waxman AB Vasc Health Risk Manag; 2007; 3(1):151-7. PubMed ID: 17583185 [TBL] [Abstract][Full Text] [Related]
12. Sitaxsentan: an endothelin-A receptor antagonist for the treatment of pulmonary arterial hypertension. O'Callaghan DS; Gaine SP Int J Clin Pract; 2006 Apr; 60(4):475-81. PubMed ID: 16620363 [TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of sitaxsentan 50 and 100 mg in patients with pulmonary arterial hypertension. Sandoval J; Torbicki A; Souza R; Ramírez A; Kurzyna M; Jardim C; Jerjes-Sánchez Díaz C; Teal SA; Hwang LJ; Pulido T; Pulm Pharmacol Ther; 2012 Feb; 25(1):33-9. PubMed ID: 22079088 [TBL] [Abstract][Full Text] [Related]
15. A review of STRIDE-2 and STRIDE-2X: the case for selective endothelin receptor blockade. Langleben D; Cacoub P Eur J Clin Invest; 2009 Jun; 39 Suppl 2():27-31. PubMed ID: 19335744 [TBL] [Abstract][Full Text] [Related]
16. Sitaxsentan in the management of pulmonary arterial hypertension. Benedict NJ Am J Health Syst Pharm; 2007 Feb; 64(4):363-8. PubMed ID: 17299175 [TBL] [Abstract][Full Text] [Related]
17. Sildenafil added to sitaxsentan in overcirculation-induced pulmonary arterial hypertension. Rondelet B; Dewachter L; Kerbaul F; Dewachter C; Hubloue I; Fesler P; Franck S; Remmelink M; Brimioulle S; Naeije R Am J Physiol Heart Circ Physiol; 2010 Oct; 299(4):H1118-23. PubMed ID: 20693396 [TBL] [Abstract][Full Text] [Related]
18. Attenuation of pulmonary vascular hypertension and cardiac hypertrophy with sitaxsentan sodium, an orally active ET(A) receptor antagonist. Tilton RG; Munsch CL; Sherwood SJ; Chen SJ; Chen YF; Wu C; Block N; Dixon RA; Brock TA Pulm Pharmacol Ther; 2000; 13(2):87-97. PubMed ID: 10799286 [TBL] [Abstract][Full Text] [Related]